JP2005516004A - 新形成の治療 - Google Patents
新形成の治療 Download PDFInfo
- Publication number
- JP2005516004A JP2005516004A JP2003550776A JP2003550776A JP2005516004A JP 2005516004 A JP2005516004 A JP 2005516004A JP 2003550776 A JP2003550776 A JP 2003550776A JP 2003550776 A JP2003550776 A JP 2003550776A JP 2005516004 A JP2005516004 A JP 2005516004A
- Authority
- JP
- Japan
- Prior art keywords
- thc
- apoptosis
- cells
- receptor
- tumor cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
前述のCBアゴニスト化合物またはその配合物の投与には、経路を限定する必要はない。オプションには、経腸(例えば経口および直腸)または非経口(例えば鼻または肺への搬送、あるいは静脈、動脈、脳、脊椎、膀胱、腹膜、筋肉または皮下領域への注射)が含まれる。治療は、単回用量またはある期間に渡る複数用量からなることが可能である。投薬量は、好ましくは、医師によって決定されるであろうが、0.01mg〜1.0g/kg/日、例えば0.1〜500mg/kg/日であることが可能である。体表平方メートルあたりの用量で表すと、化合物は、1.0mg〜1.5g/m2/日、例えば、3.0〜200.0mg/m2/日で投与可能である。
上に特に言及する成分に加えて、本発明の配合物は、問題の配合物の種類を考慮して、当該技術分野において慣用的である他の剤を含むことが可能であり、例えば経口投与に適したものは、フレーバー剤を含むことが可能である。
材料および方法
マウス:成体(6〜8週齢)メスC57BL/6マウスを米国国立衛生研究所、メリーランド州ベセスダから購入した。マウスをポリエチレンケージで飼育し、そしてげっ歯類飼料および水を自由に与えた。74±2°Fの温度に維持し、そして12時間の明/暗周期に維持した部屋でマウスを飼育した。
EL−4、LSA、およびP815ネズミ腫瘍細胞におけるCB1受容体およびCB2受容体の発現:RT−PCRによって、CB1およびCB2カンナビノイド受容体mRNAの発現を決定した(図1)。この解析によって、3つのネズミ腫瘍細胞株がすべて、CB1 mRNAおよびCB2 mRNA両方を発現することが明らかになった。
参考文献
Claims (11)
- 免疫系細胞の異常のため、療法の必要がある患者を治療する方法であって、CB2カンナビノイド受容体活性を有する化合物の療法的有効用量を投与することを含んでなる、前記方法。
- 異常が、免疫系の悪性腫瘍、自己免疫疾患、敗血症ショック、移植反応およびアレルギーからなる群より選択される、請求項1記載の方法。
- 異常が、白血病およびリンパ腫からなる群より選択される、請求項1記載の方法。
- 異常が原発性急性リンパ芽球性白血病(ALL)である、請求項1記載の方法。
- 化合物が、THCと比較した際に、減少した向精神活性を有するCB2アゴニストである、請求項1〜4のいずれか1項記載の方法。
- 選択的CB2アゴニストが、CB2受容体に対して、CB1受容体に対する親和性の少なくとも5倍の親和性を有するものから選択される、先行する請求項のいずれか1項記載の方法。
- 選択的CB2アゴニストが、CB2受容体に対して、CB1受容体に対する親和性の少なくとも10倍の親和性を有するものから選択される、請求項6記載の方法。
- 選択的CB2アゴニストが、CB2受容体に対して、CB1受容体に対する親和性の少なくとも20倍の親和性を有するものから選択される、請求項6記載の方法。
- 選択的CB2アゴニストが、CB2受容体に対して、CB1受容体に対する親和性の少なくとも100倍の親和性を有するものから選択される、請求項6記載の方法。
- 免疫系の異常、特に白血病およびリンパ腫などの免疫系の悪性腫瘍を治療するための医薬品製造のための、本発明の第一の側面の化合物の使用。
- 活性剤としてCB2アゴニストを含んでなる、免疫系の異常を治療するための薬剤組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33673201P | 2001-12-07 | 2001-12-07 | |
PCT/US2002/039310 WO2003049727A1 (en) | 2001-12-07 | 2002-12-09 | Treatment of neoplasia |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005516004A true JP2005516004A (ja) | 2005-06-02 |
JP2005516004A5 JP2005516004A5 (ja) | 2006-02-02 |
Family
ID=23317407
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003550776A Pending JP2005516004A (ja) | 2001-12-07 | 2002-12-09 | 新形成の治療 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20040259936A1 (ja) |
EP (1) | EP1461027A4 (ja) |
JP (1) | JP2005516004A (ja) |
AU (1) | AU2002357114B2 (ja) |
CA (1) | CA2468794A1 (ja) |
WO (1) | WO2003049727A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010509365A (ja) * | 2006-11-13 | 2010-03-25 | ノバルティス アーゲー | Ksp阻害剤としての置換ピラゾールおよびトリアゾール化合物 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7632955B2 (en) * | 2001-12-13 | 2009-12-15 | National Health Research Institutes | Indole compounds |
US7528165B2 (en) * | 2001-12-13 | 2009-05-05 | National Health Research Institutes | Indole compounds |
WO2005023232A2 (en) * | 2003-09-04 | 2005-03-17 | Affibody Ab | Therapeutic, screening and diagnostic methods based on the effect of cb1 receptor modulation on lymphoproliferative disorders. |
WO2005100987A1 (ja) | 2004-04-12 | 2005-10-27 | Takeda Pharmaceutical Company Limited | Gタンパク質共役型レセプタータンパク質の新規リガンドとその用途 |
TW200843761A (en) | 2004-10-28 | 2008-11-16 | Shionogi & Co | 3-carbamoyl-2-pyridone derivatives |
US7456289B2 (en) * | 2004-12-31 | 2008-11-25 | National Health Research Institutes | Anti-tumor compounds |
EP2470508A1 (en) | 2009-08-28 | 2012-07-04 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
EP2534137B1 (en) | 2010-02-08 | 2015-09-16 | Allergan, Inc. | Pyridazine derivatives useful as cannabinoid-2 agonists |
AU2012222149B2 (en) | 2011-02-25 | 2017-06-29 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
DK3395812T3 (da) | 2011-02-25 | 2022-11-28 | Arena Pharm Inc | Krystallinske former og fremgangsmåder til fremstilling af kondenserede azacykler (cannabinoid-receptor-modulatorer) |
WO2012116277A1 (en) | 2011-02-25 | 2012-08-30 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
WO2016085941A1 (en) | 2014-11-25 | 2016-06-02 | Arena Pharmaceuticals, Inc. | Processes for the preparation of cannabinoid receptor modulators |
CN114096241A (zh) * | 2019-05-16 | 2022-02-25 | 技术研究及发展基金有限公司 | 大麻素及其用途 |
CN115282279B (zh) * | 2022-08-08 | 2024-03-12 | 暨南大学附属第一医院(广州华侨医院) | CNR2通过介导DCs成熟及功能作为脓毒症急性肺损伤治疗靶点的应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1271266B (it) * | 1994-12-14 | 1997-05-27 | Valle Francesco Della | Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi |
FR2735774B1 (fr) * | 1995-06-21 | 1997-09-12 | Sanofi Sa | Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant |
EP1076653B1 (en) * | 1998-05-04 | 2004-09-29 | The University of Connecticut | Novel cannabinoids selective for the cb2 receptor |
MXPA02005100A (es) * | 1999-10-18 | 2003-09-25 | Alexipharma Inc | Derivados de pirazol antagonistas de receptor de canabinoide. |
FR2800372B1 (fr) * | 1999-11-03 | 2001-12-07 | Sanofi Synthelabo | Derives tricycliques d'acide 1-benzylpyrazole-3- carboxylique, leur preparation, les medicaments en contenant |
CA2399791A1 (en) * | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
-
2002
- 2002-12-09 JP JP2003550776A patent/JP2005516004A/ja active Pending
- 2002-12-09 US US10/497,911 patent/US20040259936A1/en not_active Abandoned
- 2002-12-09 AU AU2002357114A patent/AU2002357114B2/en not_active Ceased
- 2002-12-09 WO PCT/US2002/039310 patent/WO2003049727A1/en active Application Filing
- 2002-12-09 CA CA002468794A patent/CA2468794A1/en not_active Abandoned
- 2002-12-09 EP EP02804754A patent/EP1461027A4/en not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010509365A (ja) * | 2006-11-13 | 2010-03-25 | ノバルティス アーゲー | Ksp阻害剤としての置換ピラゾールおよびトリアゾール化合物 |
Also Published As
Publication number | Publication date |
---|---|
EP1461027A1 (en) | 2004-09-29 |
AU2002357114A1 (en) | 2003-06-23 |
WO2003049727A1 (en) | 2003-06-19 |
US20040259936A1 (en) | 2004-12-23 |
AU2002357114B2 (en) | 2008-07-24 |
EP1461027A4 (en) | 2005-09-07 |
CA2468794A1 (en) | 2003-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
McKallip et al. | Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease | |
JP2005516004A (ja) | 新形成の治療 | |
Ke et al. | Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses | |
JP5027369B2 (ja) | 腫瘍を治療する方法 | |
TWI243672B (en) | New use of compounds as antibacterial agents | |
US8841319B2 (en) | Use of 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives in leukemia management | |
EP1303265B1 (en) | Use of cox-2 inhibitors as immunostimulants in the treatment of hiv or aids | |
JP6000313B2 (ja) | 3,3’−ジインドリルメタン免疫活性化組成物 | |
JP2002544229A (ja) | 癌の化学的予防および治療のために組み合わせたdfmoおよびセレコキシブ | |
Kumar et al. | Antileukemic activity and cellular effects of the antimalarial agent artesunate in acute myeloid leukemia | |
ITMI971789A1 (it) | Farmaco attivo nel ridurre la produzione di proteina mcp-1 | |
Liu et al. | Effect of auranofin, an antirheumatic drug, on neutrophil apoptosis | |
Ben-Eliyahu et al. | Timing within the oestrous cycle modulates adrenergic suppression of NK activity and resistance to metastasis: possible clinical implications | |
JPH06234636A (ja) | インターロイキン8を阻害するためのレフルノミドの使用 | |
CN106916164A (zh) | 噻唑并嘧啶酮类ido1抑制剂及其医药用途 | |
AU2002252338B2 (en) | Taurine compounds | |
US11541030B2 (en) | Methods for the treatment of inflammation associated with infection | |
Helvaci et al. | Smoking and sickle cell diseases | |
JPH11286455A (ja) | 骨髄異形成症候群治療薬 | |
Ogino et al. | Indomethacin acts as an antitumor and anticachexic agent in colon 26-bearing CDF 1 mice | |
Wang et al. | Selective Inhibition of Natural Killer but not Natural Cytotoxic Activity in a Cloned Cell Line by Delta‐9‐Tetrahydrocannabinol | |
AU2001270902B2 (en) | Use of COX-2 inhibitors for preventing immunodeficiency | |
JP2014058497A (ja) | 炎症抑制用ベンゾキノン系化合物、ならびに、それを用いた医薬組成物およびサプリメント | |
Kaza | Mechanisms of AT101 [(-)-gossypol] induced cytotoxicity in malignant peripheral nerve sheath tumors | |
INAMSC Team | Indonesia International (bio) Medical Students' Congress 2013 Abstracts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051209 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051209 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090205 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090501 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090513 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090805 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090805 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091009 |